Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jim Cassidy

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Cancer Chemotherapy and Pharmacology|April 6, 2002
Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patientsChristopher Poole, Jill Gardiner, Chris Twelves, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2018
The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapiesKaty L Simonsen, Paula M Fracasso, Steven H Bernstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumorsAxel-R Hanauske, Jim Cassidy, Javier Sastre, et al.
The Journal of Pathology|March 29, 2002
Analysis of key cell-cycle checkpoint proteins in colorectal tumoursJudith A McKay, Joy J Douglas, Val G Ross, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancerJim Cassidy, Stephen Clarke, Eduardo Díaz-Rubio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trialsHendrik-Tobias Arkenau, Dirk Arnold, Jim Cassidy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyLeonard B Saltz, Stephen Clarke, Eduardo Díaz-Rubio, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancerTamas Hickish, Jim Cassidy, David Propper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2023
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III StudyLeonard B Saltz, Stephen Clarke, Eduardo Díaz-Rubio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancerJim Cassidy, Josep Tabernero, Chris Twelves, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Cancer Chemotherapy and Pharmacology|April 6, 2002
Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patientsChristopher Poole, Jill Gardiner, Chris Twelves, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2018
The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapiesKaty L Simonsen, Paula M Fracasso, Steven H Bernstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumorsAxel-R Hanauske, Jim Cassidy, Javier Sastre, et al.
The Journal of Pathology|March 29, 2002
Analysis of key cell-cycle checkpoint proteins in colorectal tumoursJudith A McKay, Joy J Douglas, Val G Ross, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancerJim Cassidy, Stephen Clarke, Eduardo Díaz-Rubio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trialsHendrik-Tobias Arkenau, Dirk Arnold, Jim Cassidy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyLeonard B Saltz, Stephen Clarke, Eduardo Díaz-Rubio, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancerTamas Hickish, Jim Cassidy, David Propper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2023
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III StudyLeonard B Saltz, Stephen Clarke, Eduardo Díaz-Rubio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancerJim Cassidy, Josep Tabernero, Chris Twelves, et al.
Pageof 5